| abstract |
REFERS TO 4-OXOQUINOLINE COMPOUNDS OF FORMULA I WHERE THE CY RING IS A C3-C10 CARBON RING GROUP OPTIONALLY SUBSTITUTED WITH 1-5 SELECTED SUBSTITUTES FROM THE GROUP A SELECTED FROM PHENYL, C14 ALKYLENE, HALOGEN OTHERS OR HETEROCICLICO WITH HETEROATOMOS; R1 IS A GROUP B SELECTED FROM A C3-C10 CARBON RING GROUP WITH 1 TO 5 SUBSTITUTES OR A C1-C10 ALKYL GROUP WITH 1 TO 3 SELECTED HALOGEN SUBSTITUTES; R2 IS H, C1-C4 ALKYL; R31 IS H, CYANE, OH, AMINO, NITRO, HALO, AMONG OTHERS; X IS C-R32, N; AND IT IS CR33, N WHERE R32 AND R33 ARE H, CYANE, NITRO, HALO AMONG OTHERS. THE PREFERRED COMPOUNDS ARE 6- (2,3-DICHLOROBENZYL) -1- (2-HYDROXYETHYL) -4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYL ACID, 6- (2,3-DICHLOROBENZYL) -8-FLUORINE ACID -1- (2-HYDROXYETHYL) -4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYL, 6- (2,3-DICHLOROBENZYL) -1- (2-METHANOSULPHONYLAMINOETHYL) -4-OXO-1,4- DIHYDROQUINOLINE-3-CARBOXYL, AMONG OTHERS. IT ALSO REFERS TO PHARMACEUTICAL COMPOSITIONS. THE MENTIONED COMPOUNDS ARE INHIBITORS OF HIV INTEGRASE |